Gene-editing technology developer Crispr Therapeutics has secured $38m to increase a round backed by $65m from Bayer and Vertex Pharmaceuticals to $140m.
Switzerland-based biopharmaceutical technology developer Crispr Therapeutics closed $38m in funding on Friday, boosting a series B round backed by pharmaceutical firms Bayer and Vertex Pharmaceuticals to $140m.
Crispr Therapeutics is developing medicines based on Crispr/Cas9 gene-editing technology to treat serious diseases, having licensed the technology from its scientific founder, Emmanuelle Charpentier, who co-invented the Crispr/Cas9 process.
The company raised $25m in series A funding from Versant Ventures in 2014 before closing $64m in series A and B capital in…
